chlorambucil has been researched along with Enlarged Liver in 8 studies
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lymphadenopathy, splenomegaly and hepatomegaly were seen in 52 (55%), 63 (66%) and 60 (63%) patients, respectively." | 1.34 | Chronic lymphocytic leukemia in India--a clinico-hematological profile. ( Agrawal, N; Choudhary, VP; Kumar, R; Mahapatra, M; Naithani, R; Panigrahi, I; Pati, HP; Saxena, R, 2007) |
| "Bleeding tendency was seen in 17%, infections in 17%, hyperviscosity syndrome in 12%, and cardiac failure in 25% of the patients." | 1.31 | Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. ( Angelopoulou, MK; Boussiotis, V; Dimopoulou, MN; Fessas, P; Gribabis, A; Kittas, C; Konstantopoulos, K; Kontopidou, FN; Kyrtsonis, MC; Pangalis, GA; Siakantaris, P; Vaiopoulos, GA; Vassilakopoulos, TP, 2001) |
| "A method of clinical staging of chronic lymphocytic leukemia (CLL) has been proposed which is based on the concept that CLL is a disease of progressive accumulation of nonfunctioning lymphocytes: stage O, bone marrow and blood lymphocytosis only; stage 1, lymphocytosis with enlarged nodes; stage II, lymphocytosis with enlarged spleen or liver or both; stage III, lymphocytosis with anemia; and stage IV:lymphocytosis with thrombocytopenia." | 1.25 | Clinical staging of chronic lymphocytic leukemia. ( Chanana, AD; Cronkite, EP; Levy, RN; Pasternack, BS; Rai, KR; Sawitsky, A, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tadmor, T | 1 |
| Bejar, J | 1 |
| Attias, D | 1 |
| Polliack, A | 1 |
| Agrawal, N | 1 |
| Naithani, R | 1 |
| Mahapatra, M | 1 |
| Panigrahi, I | 1 |
| Kumar, R | 1 |
| Pati, HP | 1 |
| Saxena, R | 1 |
| Choudhary, VP | 1 |
| Kyrtsonis, MC | 1 |
| Vassilakopoulos, TP | 1 |
| Angelopoulou, MK | 1 |
| Siakantaris, P | 1 |
| Kontopidou, FN | 1 |
| Dimopoulou, MN | 1 |
| Boussiotis, V | 1 |
| Gribabis, A | 1 |
| Konstantopoulos, K | 1 |
| Vaiopoulos, GA | 1 |
| Fessas, P | 1 |
| Kittas, C | 1 |
| Pangalis, GA | 1 |
| Rai, KR | 1 |
| Sawitsky, A | 1 |
| Cronkite, EP | 1 |
| Chanana, AD | 1 |
| Levy, RN | 1 |
| Pasternack, BS | 1 |
| Gallagher, CJ | 1 |
| Gregory, WM | 1 |
| Jones, AE | 1 |
| Stansfeld, AG | 1 |
| Richards, MA | 1 |
| Dhaliwal, HS | 1 |
| Malpas, JS | 1 |
| Lister, TA | 1 |
| Ferracci, C | 1 |
| Darracq, R | 1 |
| Bobin, P | 1 |
| Varieras, G | 1 |
| Richards, F | 1 |
| Spurr, CL | 1 |
| Pajak, TF | 1 |
| Blake, DD | 1 |
| Raben, M | 1 |
| Lee, SL | 1 |
| Rosner, F | 1 |
| Ruberman, W | 1 |
| Glasberg, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis[NCT00001586] | Phase 2 | 105 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839] | Phase 2 | 21 participants (Actual) | Interventional | 2012-02-22 | Completed | ||
| A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodg[NCT00479167] | Phase 2 | 1 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to Lack of accrual and interest in study) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00001586)
Timeframe: 13 years, 10.5 months
| Intervention | Participants (Number) |
|---|---|
| Intermediate-high Risk B-Cell Pts | 18 |
Changes in lymphocyte gene expression was measured by deoxyribonucleic acid (DNA) microarray analysis of circulating leukemic cells after completion of study treatment. A change in expression is defined as a >50% increase in circulating leukemic cells or a 30% decrease in circulating leukemic cells. (NCT00001586)
Timeframe: 6 hours post treatment, and 24 hours post treatment
| Intervention | Percent change in cells (Number) | |
|---|---|---|
| 6 hours post treatment (e.g. ># cells) | 24 hours post treatment (e.g. > # cells) | |
| Intermediate-high Risk B-Cell Pts | 30 | 50 |
Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 45 |
Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 95 |
8 other studies available for chlorambucil and Enlarged Liver
| Article | Year |
|---|---|
Richter syndrome in chronic lymphocytic leukaemia manifesting only as tumorous hepatomegaly.
Topics: Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2011 |
Chronic lymphocytic leukemia in India--a clinico-hematological profile.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Chlorambucil; Female; Hematologic Tests; Hepato | 2007 |
Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit.
Topics: Adult; Aged; Aged, 80 and over; Blood Viscosity; Cardiac Output, Low; Chlorambucil; Fatigue; Female; | 2001 |
Clinical staging of chronic lymphocytic leukemia.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Blood Cell Count; Bone Marrow Examination; Chlor | 1975 |
Clinical staging of chronic lymphocytic leukemia.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Blood Cell Count; Bone Marrow Examination; Chlor | 1975 |
Clinical staging of chronic lymphocytic leukemia.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Blood Cell Count; Bone Marrow Examination; Chlor | 1975 |
Clinical staging of chronic lymphocytic leukemia.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Blood Cell Count; Bone Marrow Examination; Chlor | 1975 |
Follicular lymphoma: prognostic factors for response and survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Hepatomegaly; Hum | 1986 |
[Case of Waldenström's disease with predominantly digestive symptomatology].
Topics: Adult; Chlorambucil; Diarrhea; Gastric Mucosa; Hepatomegaly; Humans; Immunoglobulin A; Immunoglobuli | 1974 |
Thymic irradiation. An approach to chronic lymphocytic leukemia.
Topics: Adult; Agammaglobulinemia; Aged; Blood Platelets; Blood Protein Electrophoresis; Bone Marrow; Bone M | 1974 |
Mu-chain disease.
Topics: Adult; Agammaglobulinemia; Anemia; Bence Jones Protein; Chlorambucil; Female; Fractures, Bone; Heavy | 1971 |